Synovitis
Active Systemic Features
Degrees of Synovitis
CONTINUED
THERAPY
Continued Disease
Activity
CONTINUED
THERAPY
Canakinumab (B)
Tocilizumab (B)
MTX or leflunomide (D)
Canakinumab (B)
Tocilizumab (B)
MTX or leflunomide
(C&D)
TNF-α inhibitor (C)
Anakinra (A)
Canakinumab (A)
Tocilizumab (A)
Anakinra (A)
Canakinumab (A)
MTX or leflunomide (C)
Tocilizumab (A)
Anakinra (C)
GC monotherapy
(oral or IV) (C)
Canakinumab (C)
Tocilizumab (C)
MD global
irrespective, AJC 0-4
Disease activity
following 1 month of
anakinra
MD global
irrespective, AJC >4
Disease activity
following 2 weeks of
GC monotherapy
MD global ≥5,
AJC irrespective
MD global <5,
AJC=0
MD global <5 &
AJC >0
Canakinumab (B)
Tocilizumab (B)
MTX or leflunomide (D)
Canakinumab (B)
Tocilizumab (B)
MTX or leflunomide (D)
TNF-α inhibitor (C)
Anakinra (A)
Canakinumab (A)
Tocilizumab (A)
Anakinra (A)
Canakinumab (A)
MTX or leflunomide (C)
Tocilizumab (A)
